SPOTLIGHT: ASCO to weigh in on cancer drug costs

As chemotherapy prices leap by 15 percent per year--and with some equally effective meds priced thousands apart--oncologists will soon get guidelines from their professional society for talking to patients about the cost of cancer treatment. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.